The initial success of Sildenafil undeniably transformed the medication landscape, but placing funds in companies primarily reliant on unbranded versions presents a challenging picture. While early returns were impressive, the cessation of patents and the emergence of less expensive alternatives have diminished the customer base. Consequently, a th